SAN DIEGO, Calif., Jan. 5, 2022 /PRNewswire/ — Rakuten Medical, Inc. (RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.
Rakuten Medical’s Vice Chairman and CEO, Mickey Mikitani, is scheduled to present virtually at approximately 10:30am PST, Monday, January 10. A live audio webcast of the presentation can be accessed by following this link. Following the completion of the presentation, a full audio recording will be available in the News section of the Rakuten Medical, Inc website at https://rakuten-med.com/us/.
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox™ therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Illuminox™ platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has 6 locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland. For more information, visit www.rakuten-med.com.
Rakuten Medical Public Relations: https://rakuten-med.com/us/contact/
SOURCE Rakuten Medical, Inc.
Related Links: https://rakuten-med.com/us